Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164917 | 1.00 | ESR2 (0.53) | ESR2TYRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19249421 | 0.92 | TYR (0.48) | ESR2TYRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29871375 | 0.83 | ALDH1A1 (0.43) | ESR2TYRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3162433 | 0.83 | ALDH1A1 (0.43) | ESR2TYRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6434521 | 0.82 | ESR2 (0.57) | ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19892266 | 0.82 | ALDH1A1 (0.46) | ESR2TYRCHRNB2CHRNA4MAPT | |
| SCHEMBL5935862 | 0.82 | ALDH1A1 (0.46) | ESR2TYRCHRNB2CHRNA4MAPT | |
| SCHEMBL31545836 | 0.82 | ALDH1A1 (0.46) | ESR2TYRCHRNB2CHRNA4MAPT | |
| SCHEMBL70722 | 0.82 | ALDH1A1 (0.46) | ESR2TYRCHRNB2CHRNA4MAPT | |
| Water SCHEMBL4974800 | 0.82 | ALDH1A1 (0.42) | ESR2TYRCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1165495-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056702-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | ESR2 426/4885TYR 9/4885CYP1A2 183/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | ESR2 426/4885TYR 9/4885CYP1A2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.